-
Something wrong with this record ?
Brief recommendations on the management of adult patients with familial hypercholesterolemia during the COVID-19 pandemic
M. Banach, PE. Penson, Z. Fras, M. Vrablik, D. Pella, Ž. Reiner, SM. Nabavi, A. Sahebkar, M. Kayikcioglu, M. Daccord, FH Europe and the International Lipid Expert Panel (ILEP),
Language English Country Netherlands
Document type Journal Article
- MeSH
- Betacoronavirus * MeSH
- Adult MeSH
- Hyperlipoproteinemia Type II complications drug therapy MeSH
- Hypolipidemic Agents therapeutic use MeSH
- Coronavirus Infections complications drug therapy MeSH
- Humans MeSH
- Disease Management * MeSH
- Pandemics MeSH
- Pneumonia, Viral complications drug therapy MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Publication type
- Journal Article MeSH
Individuals with Familial Hypercholesterolaemia (FH) are at very high risk of cardiovascular disease, which is associated with poor outcomes from coronavirus infections. COVID-19 puts strain on healthcare systems and may impair access to routine FH services. On behalf of the International Lipid Expert Panel (ILEP) and the European FH Patient Network (FH Europe), we present brief recommendations on the management of adult patients with FH during the COVID-19 pandemic. We discuss the implications of COVID-19 infections for FH patients, the importance of continuing lipid-lowering therapy where possible, issues relating to safety monitoring and service delivery. We summarise the evidence for additional benefits of statins and other lipid-lowering drugs during viral infections. The recommendations do not override in any way the individual responsibility of physicians to make appropriate and accurate decisions taking into account the condition of a given patient and the doses, rules, and regulations applicable to drugs and devices at the time of their prescription/use.
Baqiyatallah Hospital Baqiyatallah University of Medical Sciences Tehran Iran
Cardiovascular Research Centre University of Zielona Gora Zielona Gora Poland
Department of Cardiology Ege Üniversitesi School of Medicine Izmir Turkey
Department of Hypertension Chair of Nephrology and Hypertension Medical University of Lodz Poland
Neurogenic Inflammation Research Center Mashhad University of Medical Sciences Mashhad Iran
Polish Mother's Memorial Hospital Research Institute Lodz Poland
School of Pharmacy and Biomolecular Sciences Liverpool John Moores University Liverpool UK
School of Pharmacy Mashhad University of Medical Sciences Mashhad Iran
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20024857
- 003
- CZ-PrNML
- 005
- 20201222160018.0
- 007
- ta
- 008
- 201125s2020 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.phrs.2020.104891 $2 doi
- 035 __
- $a (PubMed)32389859
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Banach, Maciej $u Department of Hypertension, Chair of Nephrology and Hypertension, Medical University of Lodz, Poland; Polish Mother's Memorial Hospital Research Institute (PMMHRI), Lodz, Poland; Cardiovascular Research Centre, University of Zielona Gora, Zielona Gora, Poland. Electronic address: maciej.banach@icloud.com.
- 245 10
- $a Brief recommendations on the management of adult patients with familial hypercholesterolemia during the COVID-19 pandemic / $c M. Banach, PE. Penson, Z. Fras, M. Vrablik, D. Pella, Ž. Reiner, SM. Nabavi, A. Sahebkar, M. Kayikcioglu, M. Daccord, FH Europe and the International Lipid Expert Panel (ILEP),
- 520 9_
- $a Individuals with Familial Hypercholesterolaemia (FH) are at very high risk of cardiovascular disease, which is associated with poor outcomes from coronavirus infections. COVID-19 puts strain on healthcare systems and may impair access to routine FH services. On behalf of the International Lipid Expert Panel (ILEP) and the European FH Patient Network (FH Europe), we present brief recommendations on the management of adult patients with FH during the COVID-19 pandemic. We discuss the implications of COVID-19 infections for FH patients, the importance of continuing lipid-lowering therapy where possible, issues relating to safety monitoring and service delivery. We summarise the evidence for additional benefits of statins and other lipid-lowering drugs during viral infections. The recommendations do not override in any way the individual responsibility of physicians to make appropriate and accurate decisions taking into account the condition of a given patient and the doses, rules, and regulations applicable to drugs and devices at the time of their prescription/use.
- 650 _2
- $a dospělí $7 D000328
- 650 12
- $a Betacoronavirus $7 D000073640
- 650 _2
- $a koronavirové infekce $x komplikace $x farmakoterapie $7 D018352
- 650 12
- $a management nemoci $7 D019468
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hyperlipoproteinemie typ II $x komplikace $x farmakoterapie $7 D006938
- 650 _2
- $a hypolipidemika $x terapeutické užití $7 D000960
- 650 _2
- $a pandemie $7 D058873
- 650 _2
- $a virová pneumonie $x komplikace $x farmakoterapie $7 D011024
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Penson, Peter E $u School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK.
- 700 1_
- $a Fras, Zlatko $u Division of Medicine, Centre for Preventive Cardiology, University Medical Centre Ljubljana, Medical Faculty, University of Ljubljana, Ljubljana, Slovenia.
- 700 1_
- $a Vrablik, Michal $u Third Department of Internal Medicine, First Faculty of Medicine, Charles University and General Faculty Hospital in Prague, Prague, Czech Republic.
- 700 1_
- $a Pella, Daniel $u Department of Cardiology of the East Slovak Institute of Cardiovascular Disease and Faculty of Medicine PJ Safarik University, Kosice, Slovak Republic.
- 700 1_
- $a Reiner, Željko $u Department of Internal Diseases University Hospital Center Zagreb School of Medicine, Zagreb University, Zagreb, Croatia.
- 700 1_
- $a Nabavi, Seyed Mohammad $u Baqiyatallah Hospital, Baqiyatallah University of Medical Sciences, Tehran, Iran.
- 700 1_
- $a Sahebkar, Amirhossein $u Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
- 700 1_
- $a Kayikcioglu, Meral $u Department of Cardiology, Ege Üniversitesi School of Medicine, Izmir, Turkey.
- 700 1_
- $a Daccord, Magdalena $u FH Europe, Europe. Electronic address: md@fheurope.org.
- 710 2_
- $a FH Europe and the International Lipid Expert Panel (ILEP)
- 773 0_
- $w MED00005744 $t Pharmacological research $x 1096-1186 $g Roč. 158, č. - (2020), s. 104891
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32389859 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201222160014 $b ABA008
- 999 __
- $a ok $b bmc $g 1599002 $s 1115543
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 158 $c - $d 104891 $e 20200507 $i 1096-1186 $m Pharmacological research $n Pharmacol Res $x MED00005744
- LZP __
- $a Pubmed-20201125